Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics across various medical fields, including inflammation, oncology, bone health, cardiovascular disease, nephrology, and neuroscience. Its primary revenue sources come from a diverse portfolio of products, with significant contributions from Enbrel (approximately 20%), Neulasta (15%), and Prolia (10%), among others. The company serves healthcare providers such as physicians, hospitals, and pharmacies, distributing its products through wholesale distributors and direct-to-consumer channels. Factors supporting Amgen's endurance include its strong pipeline of innovative therapies and established market presence, while challenges may arise from patent expirations and competition from biosimilars.
—
Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics across various medical fields, including inflammation, oncology, bone health, cardiovascular disease, nephrology, and neuroscience. Its primary revenue sources come from a diverse portfolio of products, with significant contributions from Enbrel (approximately 20%), Neulasta (15%), and Prolia (10%), among others. The company serves healthcare providers such as physicians, hospitals, and pharmacies, distributing its products through wholesale distributors and direct-to-consumer channels. Factors supporting Amgen's endurance include its strong pipeline of innovative therapies and established market presence, while challenges may arise from patent expirations and competition from biosimilars.
—
Daily adjusted close
Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics across various medical fields, including inflammation, oncology, bone health, cardiovascular disease, nephrology, and neuroscience. Its primary revenue sources come from a diverse portfolio of products, with significant contributions from Enbrel (approximately 20%), Neulasta (15%), and Prolia (10%), among others. The company serves healthcare providers such as physicians, hospitals, and pharmacies, distributing its products through wholesale distributors and direct-to-consumer channels. Factors supporting Amgen's endurance include its strong pipeline of innovative therapies and established market presence, while challenges may arise from patent expirations and competition from biosimilars.